<?xml version="1.0" encoding="UTF-8"?>
<ref id="B113-biomedicines-08-00060">
 <label>113.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Jhawar</surname>
    <given-names>S.R.</given-names>
   </name>
   <name>
    <surname>Thandoni</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Bommareddy</surname>
    <given-names>P.K.</given-names>
   </name>
   <name>
    <surname>Hassan</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Kohlhapp</surname>
    <given-names>F.J.</given-names>
   </name>
   <name>
    <surname>Goyal</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Schenkel</surname>
    <given-names>J.M.</given-names>
   </name>
   <name>
    <surname>Silk</surname>
    <given-names>A.W.</given-names>
   </name>
   <name>
    <surname>Zloza</surname>
    <given-names>A.</given-names>
   </name>
  </person-group>
  <article-title>Oncolytic virusesâ€”Natural and genetically engineered cancer immunotherapies</article-title>
  <source>Front. Oncol.</source>
  <year>2017</year>
  <volume>7</volume>
  <pub-id pub-id-type="doi">10.3389/fonc.2017.00202</pub-id>
 </element-citation>
</ref>
